Younger children are more responsive to amblyopia treatment

Article

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years.

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years, according to a study featured in Archives of Ophthalmology.

Dr Jonathon M. Holmes and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, performed a meta-analysis of 4 recently completed randomized amblyopia treatment. This was done to evaluate the correlation between age and improvement in logMAR amblyopic eye visual acuity.

Each analysis was adjusted for spherical equivalent refractive error in the affected eye, type of amblyopia, baseline amblyopic eye visual acuity, previous amblyopia treatment, study treatment and protocol.

The results demonstrated that children aged between 7 and 13 years had a significantly reduced response rate to amblyopia treatment than children less than 7 years of age. However, no differences were found between those aged 3 to 5 years and those aged between 5 and 7 years with moderate ambylopia. Children aged between 3 to 5 years with severe ambylopia had a greater response to treatment than those aged 5 to 7 years.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
© 2025 MJH Life Sciences

All rights reserved.